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A B S T R A C T
Background: The SPYRAL HTN-OFF MED Pivotal trial demonstrated that RDN was efficacious compared to a
sham control. The underlying model was an extension of the analysis of covariance (ANCOVA) model, adjusted
for baseline blood pressure (BP), and allowed borrowing of information from the previously reported feasibility
study using a novel Bayesian method. Fundamental to the estimation of a treatment effect for efficacy are a mul-
titude of statistical modelling assumptions, including the role of outliers, linearity of the association between
baseline BP and outcome, and parallelism of the treatment effect difference over the baseline BP range. In this
report, we examine the validity of these assumptions to verify the robustness of the treatment effect measured.
Methods: We examined the requisite modelling assumptions of the ANCOVA model fitted to the SPYRAL HTN-
OFF MED Pivotal trial using Bayesian methods. To address outliers, we fit a robust regression model (with
heavy tailed errors) to the data with diffuse weakly informative prior distributions on the parameters. To ad-
dress linearity, we replaced the linear baseline term by a natural spline term with 4 degrees of freedom. To ad-
dress parallelism, we refit the ANCOVA model with an interaction term for treatment arm and baseline BP.
Results: ANCOVA models were fitted to the trial data (pooled across the feasibility and pivotal cohorts) using
Bayesian methodology with diffuse (non-informative) prior distributions. The modelling assumptions inherent
to the ANCOVA models were shown to be broadly satisfied. A robust ANCOVA model yielded a posterior
treatment effect of -4.1 mmHg (95% credible interval: -6.3 to -1.9) indicating the influence of outlier values
was small. There was moderate evidence of an interaction term effect between baseline BP and treatment, but
no evidence of gross violation of linearity in baseline BP.
Conclusion: The posterior treatment effect estimate is shown to be robust to underlying model assumptions, thus
further supporting the evidence of RDN to be an efficacious treatment for resistant hypertension.
1. Introduction
The SPYRAL HTN-OFF MED Pivotal trial demonstrated a reduction
in blood pressure after renal denervation (RDN), and employed a novel
Bayesian methodology whereby an informative prior distribution was
constructed from the pilot study, and a stochastic comparison approach
was used to down-weight the influence depending on the similarity
with the pivotal data [1]. The results were consistent with prespecified
analyses whereby a classical analysis of covariance (ANCOVA) model
was fitted to the pooled (pilot + pivotal) cohorts that was supported by
the similarity of the data between the cohorts. Irrespective of the ap-
proach taken to combine the pilot and pivotal cohorts in the Bayesian
framework, the fundamental underlying model remains consistent: the
ANCOVA model [2]. It is of interest to inspect the underlying modelling
assumptions in order to gauge the potential impact on the treatment ef-
fect.
Abbreviations: ASBP, Ambulatory Systolic Blood Pressure; SBP, Systolic Blood Pressure; RDN, Renal Denervation; ANCOVA, analysis of covariance.
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2. Methods
2.1. Study design
The SPYRAL HTN-OFF MED Pivotal trial was a multicentre, interna-
tional, prospective, single-blinded, randomized, sham-controlled trial
conducted in accordance with the Declaration of Helsinki, and the trial
protocol was approved by the Institutional Review Boards or Ethics
Committee from 44 study sites in Europe, the United States, Japan and
Australia. Patients provided written informed consent. Details regard-
ing trial design and enrolment criteria have been published previously
[1,3]. The primary efficacy endpoint was reduction in ambulatory sys-
tolic BP (ASBP) between RDN and sham control groups based on 24-h
ambulatory BP measurement at 3-month follow-up.
The SPYRAL HTN-OFF MED Pivotal trial prespecified a Bayesian
analysis that used data from the pilot study to construct an informative
prior distribution, that was subsequently updated with data from the
pivotal study. In particular, the prior distribution was constructed using
a discount power prior methodology that allows for the prior informa-
tion to be down-weighted according to the concordance between the
prior and pivotal outcomes data. The discounting (power) parameters
estimated for ASBP in the pivotal study were 1.00 (RDN) and 0.75 (con-
trol), with values approaching 1 indicating strong similarity between
the pilot and pivotal datasets.
2.2. Bayesian ANCOVA
The SPYRAL HTN-OFF MED Pivotal trial adopted an unconventional
parameterisation of the analysis of covariance (ANCOVA) model [1].
Namely, for subject , randomized to treatment (sham-control)
or (RDN), the change from baseline in 3-month systolic blood
pressure (SBP), , is modelled as
where is the baseline SBP measurement for subject , is the sample
mean of baseline SBP measures in the pivotal data, and denotes a ran-
dom error term assumed to be normally distributed with mean zero and
constant variance. Under this parameterisation, the sham-adjusted
treatment effect is calculated as . This prespecified model
allowed for different prior distributions (as well as different discount-
ing) to be applied in the control and treatment arms. Since it was shown
that there was a large amount of similarity in data-borrowing between
the prior and pivotal data for the two arms, in the following, we revert
to the classical ANCOVA regression model,
We apply Bayesian regression analyses by placing prior distributions
on the model coefficients and variance term, which summarises prior
knowledge. By applying Bayes’ theorem [4,5], we mathematically up-
date the joint prior distribution by the likelihood (determined from the
data and model) to derive a posterior distribution. This posterior distri-
bution represents beliefs after having observed the data and can then be
used to produce probability statements regarding the treatment effect
of RDN. In particular, we can calculate the probability of treatment effi-
cacy conditional on the data ( ), , and summarise the distrib-
ution.
Although the primary focus here is on the pooled data, Bayesian re-
gression models were fitted separately to the pilot, pivotal, and pooled
datasets to illustrate the commensurability of the treatment effects. In
each case, flat (so-called ‘non-informative’) prior distributions were as-
sumed for the unknown parameters, essentially allowing for the trial
data to drive the posterior distribution.
2.3. Modelling assumptions
Independent of whether a Bayesian or frequentist statistical para-
digm is adopted for an analysis, ANCOVA regression models depend on
several modelling assumptions. We examine three key assumptions: 1)
the influence of outliers; 2) the linearity assumption of SBP change with
baseline SBP; and 3) the parallelism assumption. In each case, we re-
stricted these supportive analyses to the pooled data.
2.3.1. Outliers
To address the outliers, we fit a robust ANCOVA regression model
where the errors, , are assumed to be independently distributed with
Student t-errors with an unknown degrees of freedom parameter. It is
evident from simple graphical analyses that there are outliers in the
SPYRAL HTN-OFF MED Pivotal trial. Student t-distributions have wider
tails than normally distributed errors meaning they are less sensitive to
outliers. We place default weakly informative prior distributions on the
parameters, including the degrees of freedom parameter.
2.3.2. Linearity
The model assumes the endpoint is linear in baseline SBP, with slope
. To evaluate this assumption, we replace the linear baseline SBP
term, , by a natural spline term with 4 degrees of freedom (3 internal
knots placed at quartiles).
2.3.3. Parallelism
The regression lines of outcome, , are assumed to be parallel for
each treatment arm over the range of values. To evaluate this as-
sumption, we refit the ANCOVA model by mean centering the baseline
SBP, , and including an additional interaction term between treat-
ment and [centered] baseline SBP, .
2.4. Statistical analysis
All Bayesian models are fitted using the Stan software with R (ver-
sion 4.0.1; R Foundation for Statistical Computing, Vienna, Austria).
The package ‘brms’ (version 2.13.0) is used to fit the robust regression
model. The ‘rstanarm’ (version 2.19.3) package is used to fit all other
models. Posterior distributions were sampled using Markov chain
Monte Carlo methods with 4 chains (with between 10,000 and 50,000
samples per chain) and the first half of each chain discarded as burn-in.
Gelman-Rubin statistics were used as a diagnostic to assess conver-
gence. Posterior treatment effects are summarised by means and 95%
credible intervals (95% CrI), the posterior probability that RDN is effec-
tive (i.e. ), and graphically summarised using kernel density
plots.
3. Results
Primary endpoint results have been previously published, with a
treatment difference of -3.9 mmHg (95% CrI: -6.2 to -1.6) favouring
RDN over sham control for 3-month change in ASBP, and >0.999 pos-
terior probability of efficacy [1]. Applying the simpler ANCOVA model
(above) to the data yields a posterior treatment effect of -4.0 mmHg
(95% CrI: -6.2 to -1.8), with corresponding probability of efficacy >
0.999. Analyses demonstrated some influence of outliers leading to a
slightly larger treatment effect relatively to standard normal error
model (-4.1 mmHg, Fig. 1A). Relaxing the linearity assumption also did
not influence the treatment effect (-4.0 mmHg; 95% CrI: -6.2 to -1.8),
with demonstrable evidence of a linear association (Fig. 1B).
The standard ANCOVA model posits that the baseline-adjusted
treatment effect is constant over the range of baseline ASBP values. By
including an interaction term between baseline ASBP and treatment we
allow for differential treatment effects over varying baseline ASBP val-
ues (Fig. 2A and B). At the baseline ASBP sample mean
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Fig. 1. A) Posterior distribution of ANCOVA baseline ASBP adjusted treatment effect for RDN (versus sham control) with normal errors and Student-t distributed er-
rors. B). Posterior natural spline model fit (with 95% credible bands) of association between baseline ASBP and 3-month ASBP change from baseline for RDN.
Fig. 2. A: Posterior model fits (with 95% credible bands) based on an ANOCVA model with interaction term between treatment and baseline ASBP. B: Posterior
treatment effect versus baseline ASBP, calculated as the vertical distance between the RDN and control lines in panel A. Black-dashed lines denote the 95% credible
interval band. Red-dashed line denotes null effect; blue-dashed line denotes the treatment effect assuming no interaction term. C: Histogram of baseline 24-hr ASBP
values. Red-dashed line denotes the sample mean. D: Posterior distribution of the interaction term from the ANCOVA model. The blue shaded area to the left of zero
(red-dashed line) denotes the posterior probability of a negative interaction term (0.86). (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
(150.8 ± 7.7 mmHg; Fig. 2C) the posterior treatment effect is -
4.0 mmHg (95% CrI: -6.2 to -1.8), with >0.999 posterior probability of
efficacy. The interaction term coefficient was -0.2 mmHg (95% CrI: -0.5
to 0.1). Although the credible interval contains zero, corresponding
with no interaction, the posterior probability of the interaction being
negative was 0.86 (Fig. 2D).
4. Discussion
Application of Bayesian methods to clinical trial design has become
increasingly commonplace in both pharmaceutical and device clinical
trials. As a primary analytical method, a Bayesian approach permits
greater efficiency in trial design by reducing trial sample size and re-
dundancy by enabling synthesis of accruing information. For the
SPYRAL HTN-OFF MED Pivotal study, Bayesian methods were used to
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incorporate the previously published data from a corresponding pilot
study within an adaptive design. There was substantial evidence to sup-
port the overall poolability of the data, which facilitates simpler model-
ling approaches. Another advantage of the Bayesian paradigm is the
ability to report posterior probabilities of the underlying hypothesis of
interest, as opposed to frequentist P values that are routinely misunder-
stood.
Modelling assumptions are inherent to analysis approaches em-
ployed in the SPYRAL HTN-OFF MED Pivotal trial, irrespective of
whether one adopts a Bayesian or frequentist paradigm, or, in the case
of the latter, whether one adopts the complex discount power prior
methodology employed in the primary analysis or the simpler diffuse
prior approach used in this report. To date there has been little atten-
tion given to these assumptions. Herein, we investigated these assump-
tions to ensure the primary reported results were robust to these as-
sumptions, including outliers, linearity, and parallelism. In each case
reported, there was overwhelming evidence to support efficacy.
5. Conclusions
The SPYRAL HTN-OFF MED Pivotal trial employed a novel yet com-
plex prespecified Bayesian methodology. The underlying model as-
sumptions are demonstrated as being suitably satisfied, or, where slight
departures were observed (as was the case with outliers), the impact on
the treatment effect was shown to be very small. It is therefore conclu-
sive that RDN is efficacious in lowering blood pressure.
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